Celularity, Inc. headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified natural killer (NK) cells, genetically-modified NK cells, T-cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
Company profile
Ticker
CELU, CELUW
Exchange
Website
CEO
Robert Joseph Hariri
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
GX Acquisition Corp.
SEC CIK
Corporate docs
IRS number
831702591
CELU stock data
Latest filings (excl ownership)
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Entry into a Material Definitive Agreement
15 Mar 24
8-K
Material Modifications to Rights of Security Holders
26 Feb 24
8-K
Departure of Directors or Certain Officers
22 Feb 24
8-K
Regulation FD Disclosure
12 Feb 24
DEF 14A
Definitive proxy
2 Feb 24
PRE 14A
Preliminary proxy
23 Jan 24
8-K
Entry into a Material Definitive Agreement
17 Jan 24
8-K
Celularity Announces Net Sales and Total Revenue Expectations
9 Jan 24
10-Q
2023 Q3
Quarterly report
2 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 15.10 mm | 15.10 mm | 15.10 mm | 15.10 mm | 15.10 mm | 15.10 mm |
Cash burn (monthly) | 937.00 k | 3.53 mm | 33.09 mm | 15.56 mm | 2.77 mm | 5.33 mm |
Cash used (since last report) | 6.26 mm | 23.60 mm | 221.12 mm | 104.02 mm | 18.54 mm | 35.60 mm |
Cash remaining | 8.84 mm | -8.51 mm | -206.02 mm | -88.92 mm | -3.44 mm | -20.51 mm |
Runway (months of cash) | 9.4 | -2.4 | -6.2 | -5.7 | -1.2 | -3.8 |
Institutional ownership, Q2 2022
0.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 5.70 mm |
Total shares | 517.77 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Linden Capital | 517.77 k | $5.70 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Apr 24 | Kyle Fletcher | Class A Common Stock | Payment of exercise | Dispose F | No | No | 4.11 | 20 | 82.20 | 21,085 |
13 Apr 24 | John R Haines | Class A Common Stock | Payment of exercise | Dispose F | No | No | 4.11 | 576 | 2.37 k | 38,373 |
13 Apr 24 | David C Beers | Class A Common Stock | Payment of exercise | Dispose F | No | No | 4.11 | 360 | 1.48 k | 23,983 |
13 Apr 24 | Hariri Robert J | Class A Common Stock | Payment of exercise | Dispose F | No | No | 4.11 | 1,154 | 4.74 k | 2,855,889 |
13 Apr 24 | Stephen Brigido | Class A Common Stock | Payment of exercise | Dispose F | No | No | 4.11 | 268 | 1.10 k | 19,472 |
News
Celularity Says That Its Expected Net Sales For Q1 2024 Are Trending Ahead Of The Expectations It Announced In February For Its Advanced Biomaterial Products And Biobanking Businesses; Implements Planned 2024 SG&A Reductions And Manufacturing Ramp For Advanced Biomaterial Products
15 Apr 24
Celularity To Present Data Showing Senescent Cell Elimination By Off-The-Shelf Natural Killer Cells Derived From Human Placental Cells
8 Apr 24
Celularity Receives Healthcare Common Procedure Coding System Q Code Approval From The U.S. Centers For Medicare & Medicaid Services For Biovance 3L
26 Mar 24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
13 Mar 24
Workday, Domino's And 3 Stocks To Watch Heading Into Monday
26 Feb 24
Press releases
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
19 Apr 24
Celularity Abstract "Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials" Accepted at ORS Tendon Conference 2024
18 Apr 24
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products
15 Apr 24
Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells
8 Apr 24
Kuehn Law Encourages Investors of Celularity Inc. to Contact Law Firm
22 Mar 24